The Department of Veterans Affairs (VA) is issuing a presolicitation notice for Request for Proposal (RFP) 36E79725R0049 regarding the procurement of Atropine Sulfate Syringes. This procurement is restricted to U.S.-made products to comply with public interest requirements. Interested vendors must certify their products meet the U.S.-made definition and must submit proposals for a one-year contract with four optional renewal periods. The estimated annual requirement is approximately 97,550 individual syringes of Atropine Sulfate 0.1mg/ml, packaged in 10ml syringes. Proposals will be assessed based on the unit price of syringes, and products must be labeled with the contractor's unique National Drug Code (NDC). The RFP will be available electronically on or around August 28, 2025, with a closing date of September 30, 2025. Interested bidders must monitor SAM.gov for updates, and inquiries should be directed to the Contracting Officer, Diana Martinez, via email.

This government solicitation (SF-1449, Solicitation Number 36E79725R0049) outlines a request for proposals to establish a national contract for Atropine Sulfate Syringes for the Department of Veterans Affairs (VA) Pharmaceutical Prime Vendor (PPV) Program. The contract is for a base year with four one-year options. Key requirements include proposing U.S.-made products, providing prices for all years with a 0.5% Cost Recovery Fee, and submitting an 11-digit National Drug Code (NDC) unique to the offeror. Offerors must be either the manufacturer or a distributor with a Letter of Commitment from the manufacturer. All proposed products must have FDA-approved drug applications and comply with Drug Supply Chain Security Act (DSCSA) requirements, including serialized transaction information. Manufacturers must maintain an acceptable cGMP status with the FDA. The document details contract terms, including payment through the PPV program, backorder procedures, packaging, barcoding, and recall protocols.